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Abstract The synthesis of a novel unsymmetrical dihy-
dropyridine, bearing carboxy methyl and carbomethoxy
groups at C(3) and C(5), respectively, has been achieved
by applying the modified Hantzsch-type condensation,
which involves the Michael addition of Knoevenagel
adduct with an enamine. The product obtained was char-
acterized by spectroscopic techniques and finally con-
firmed by X-ray diffraction studies. The title compound
C17H19NO3 crystallizes in Monoclinic crystal class in
space group P21/c with cell parameters a = 9.9130(12) A˚,
b = 7.3320(5) A˚, c = 22.018(3) A˚, b = 109.637(3), V =
1507.2(3) A˚3 and Z = 4. The final residual factor R1 =
0.0642. The structure exhibits both intra and inter-molec-
ular hydrogen bonding of the type C–HO and N–HO.
The pyridine ring gives boat conformation.
Keywords 1,4-Dihydropyridine  Hantzsch synthesis 
Crystal structure  Hydrogen bonding
Introduction
1,4-Dihydropyridine derivatives (1,4-DHPs) form a class of
heterocyclic compounds with interesting pharmacological
and biological properties [1–9]. It is well known that the
1,4-DHP nucleus serves as the scaffold of important car-
diovascular drugs and it has been well established that the
calcium modulator activity of this family of compounds is
determined by structural requirements [10–14]. The sys-
tematic structural modification of the 1,4-DHP ring yields
different compounds used in the treatment of hypertension
and angina pectoris [15–23]. The most prominent of these
compounds is nifedipine, which was the first generation
calcium channel blocker, marketed by Bayer [24]. Since
then, a wide variety of novel compounds belonging to the
second and third generations of new biologically active
substances from the 1,4-DHP class have been developed in
order to obtain larger bioavailabilities or greater tissue
selectivity [25, 26]. Felodipine, lercanidipine, and clinidi-
pine are examples of newer DHP-calcium antagonists,
which are effective antihypertensive compounds.
Up to now, 1,4-Dihydropyridine derivatives (1,4-DHPs)
are still the most potent group of calcium channel modulators
and, therefore, the design of DHP-calcium channel modu-
lators has prompted the studies to investigate the functional
and geometrical requirements at the DHP binding site [27].
Structure–activity relationships (SAR) show that the com-
bination of the substituents at the C(3), C(4) and C(5) posi-
tions of nifedipine modulates the activity [28] and tissue
selectivity [29], while the nature and position of C(4)-aryl
ring substituents were determinant of voltage-dependent
calcium channel (VDCC) antagonist activity. In general, the
presence of an aryl group at C4, and esters, acyl, sulphonyl or
nitrile groups at C(3) and C(5) of the 1,4-DHP ring has
proved to be a fundamental requirement for the pharmaco-
logical activity [30–32]. The majority of 1,4-dihydropyri-
dines synthesized possess similar groups (acetyl or ester)
at C(3) and C(5). However, very few unsymmetrical
1,4-dihydropyridines having an acetyl group as one of the
substituents on C(3) and C(5) positions, have been reported.
Earlier Tumor specific-cytotoxicity and MDR reversal
activity of fifteen unsymmetric 1,4-dihydropyridines were
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studied [33]. These fifteen compounds containing substi-
tuted Carbamoyl group at C(5) while C(3) position was
alternatively occupied by various functional groups like
cyano, acetyl, methyl ester and ethyl ester. The C-3 posi-
tion of phenyl ring of 1,4-dihydropyridine was fixed by
NO2 group [34]. The majority of the tested compounds
were found to be the most effective MDR modulators and
these derivatives caused a dose-dependent inhibition of the
MDR p-glycoprotein [13, 35].
Previous studies indicated that the substituted aryl ring
could influence the degree of puckering of the 1,4-dihydro-
pyridine ring, which in turn may be related to the activity
[36]. It was very pertinent to reinvestigate the functionality
of various groups of 4-phenyl ring especially in unsymmetric
dihydropyridines. So in the current work, earlier substitu-
tions [37] were removed and unsubstituted phenyl ring
attached to 1,4-dihydropyridine structure was synthesized. It
was necessary to establish the divergence of calcium channel
antagonism and cardiovascular activity [38] to achieve bet-
ter mutidrug resistance (MDR) related reverting aptitude due
to p-glycoprotein [39, 40] and therefore the cardiovascular
functionality essentially inherited in 2-nitro/3-nitro group
of phenyl ring of many DHP drug molecules and one of
the esteric linkage is removed to introduce acetyl group in
1,4-dihydropyridine ring in the investigated molecule.
Owing to the potency of 1,4-Dihydropyridine deriva-
tives (1,4-DHPs) and as a continuation of our previous
work [41, 42], the title compound was synthesized by using
modified Hantzsch-type condensation which involved
Michael addition of a Knoevenagel adduct, benzylidene-
acetylacetone with an enamine, methyl-3-aminocrotonate.
The structure of the product obtained was confirmed by
X-ray crystallography.
Synthesis
Synthesis of 2,6-Dimethyl-3-Acetyl-5-Carbomethoxy-
4-Phenyl-1,4-Dihydropyridine
A mixture of substituted benzylideneacetylacetone
(0.01 mol) and methyl-3-aminocrotonate (0.01 mol) was
refluxed on an oil bath for 18 h using isopropyl alcohol as a
solvent (25 mL). The reaction was monitored by TLC.
After completion of the reaction, the reaction mass was
cooled to room temperature. The excess of solvent was
distilled out with the help of rotavapour and residual pale
yellow-orange oil was crystallized from ether:ethanol
(20:1) gave faint yellow crystals. (M.P. 170–172 C; Yield,
69%).
Table 1 Crystal data and structure refinement
Empirical formula C17H19NO3
Formula weight 285.33
Temperature 293(2) K
Wavelength 0.71073 A˚
Crystal system Monoclinic
Spacegroup P21/c
Cell dimensions a = 9.9130(12) A˚
b = 7.3320(5) A˚
c = 22.018(3) A˚
b = 109.637(3)
Volume 1507.2(3) A˚3
Z 4
Density (calculated) 1.257 Mg m-3
Absorption coefficient 0.086 mm-1
F000 608
Crystal size 0.3 9 0.3 9 0.25 mm
Theta range for data collection 2.18–25.02
Index ranges -10 B h B 10
-7 B k B 7
-26 B l B 26
Reflections collected 4013
Independent reflections 2257 [R(int) = 0.0209]
Refinement method Full-matrix least-squares on F2
Data/restraints/parameters 2257/0/195
Goodness-of-fit on F2 1.083
Final R indices [I [ 2r(I)] R1 = 0.0642, wR2 = 0.1798
R indices (all data) R1 = 0.0770, wR2 = 0.1945
Extinction coefficient 0.136(18)
Largest diff. peak and hole 0.676 and -0.294 e A˚-3
H3COOC
H3C NH2
+
CH3O
CH3
O
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Isopropyl
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Fig. 1 Reaction scheme
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Anal. Calc. (in %) C = 71.56, H = 6.71, N = 4.91;
Found C = 71.49, H = 6.80, N = 4.95.
IR (KBr, cm-1): 3396(N–H stretching), 3030(C–H
stretching, Asymmetric), 2930(C–H stretching, Sym-
metric), 1703(C=O stretching, ester), 1670(C=O stretch-
ing, ketone), 1589(N–H deformation).
1H NMR (300 MHz, d ppm): 7.12–7.22 (m, 5H, Ar–H),
6.07 (s, 1H, NH), 5.01 (s, 1H, CH), 3.70 (s, 3H,
COOCH3), 2.34 (s, 3H, COCH3), 2.30 (s, 3H, CH3), 2.16
(s, 3H, CH3).
MS (m/z): 285.
Method of Crystallization
The pure 2,6-Dimethyl-3-acetyl-5-carbomethoxy-4-phe-
nyl-1,4-dihydropyridine (0.25 g) was taken in 25 mL of
isopropyl alcohol. The resulting solution was warmed with
charcol on a water bath and 8–10 drops of DMF was added
to the solution. The solution was filtered while hot through
whatmann 42 filter paper. The solution was kept in a
stopper conical flask slightly opened. Crystals grew after
30 days due to thin layer evaporation. They were filtered
and washed with chilled methanol. The method employed
for synthesis is shown in Fig. 1.
Crystal Structure Determination
A single crystal of the title compound with dimensions
0.30 9 0.25 9 0.25 mm was chosen for the X-ray dif-
fraction study. The data were collected on a DIPLabo
Image Plate system equipped with a normal focus, 3KW
sealed X-ray source (graphite monochromated Mo Ka).
The crystal to detector distance was fixed at 120 mm with
the detector area of 441 9 240 mm2. Thirty six frames of
data were collected at room temperature by the oscillation
method. Each exposure of the image plate was set to 400 s.
Successive frames were scanned in steps of 5 per minute
with an oscillation range of 5. Image processing and data
reduction were done using Denzo [43]. The reflections
were merged with Scalepack [44]. All the frames could be
indexed using a monoclinic lattice. Absorption correction
was not applied. The structure was solved by direct
Table 2 Bond length (A˚)
Atoms Length
N1–C6 1.374(3)
N1–C2 1.379(3)
C2–C3 1.357(3)
C2–C7 1.493(3)
C3–C9 1.462(3)
C3–C4 1.512(3)
C4–C16 1.528(3)
C4–C5 1.529(3)
C5–C6 1.367(3)
C5–C13 1.453(3)
C6–C8 1.498(3)
C9–O10 1.205(3)
C9–O11 1.345(3)
O11–C12 1.432(3)
C13–O14 1.228(3)
C13–C15 1.466(4)
C16–C21 1.386(4)
C16–C17 1.387(4)
C17–C18 1.386(4)
C18–C19 1.373(5)
C19–C20 1.364(6)
C20–C21 1.389(5)
Table 3 Bond angles ()
Atoms Angle
C6–N1–C2 124.74(2)
C3–C2–N1 118.5(2)
C3–C2–C7 128.1(2)
N1–C2–C7 113.4(2)
C2–C3–C9 121.5(2)
C2–C3–C4 119.46(2)
C9–C3–C4 118.78(2)
C3–C4–C16 112.37(2)
C3–C4–C5 111.42(2)
C16–C4–C5 109.53(2)
C6–C5–C13 125.41(2)
C6–C5–C4 118.84(2)
C13–C5–C4 115.75(2)
C5–C6–N1 118.12(2)
C5–C6–C8 128.8(2)
N1–C6–C8 113.1(2)
O10–C9–O11 121.4(2)
O10–C9–C3 126.9(2)
O11–C9–C3 111.6(2)
C9–O11–C12 116.7(2)
O14–C13–C5 119.9(2)
O14–C13–C15 117.5(2)
C5–C13–C15 122.6(2)
C21–C16–C17 118.7(3)
C21–C16–C4 120.3(2)
C17–C16–C4 121.0(2)
C18–C17–C16 120.2(3)
C19–C18–C17 120.6(3)
C20–C19–C18 119.7(3)
C19–C20–C21 120.5(3)
C16–C21–C20 120.3(3)
776 J Chem Crystallogr (2011) 41:774–778
123
methods using SHELXS-97 [45]. Least-squares refinement
using SHELXL-97 [45] with isotropic temperature factors
for all the non-hydrogen atoms converged the residual R1
to 0.0770.
Subsequent refinements were carried out with aniso-
tropic thermal parameters for non-hydrogen atoms and
isotropic temperature factors for the hydrogen atoms which
were placed at chemically acceptable positions. The
hydrogen atoms were allowed to ride on their parent atoms.
After eight cycles of refinement the residual converged to
0.0642. The details of crystal data and refinement are given
in Table 1. Tables 2 and 3 give the list of bond lengths and
bond angles, respectively, which are in good agreement
with the standard values. Table 4 gives atomic coordinates
and equivalent thermal parameters of the non-hydrogen
atoms and Table 5 gives hydrogen-bonding geometry. The
ORTEP of the molecule with thermal ellipsoids drawn at
50% probability is shown in Fig. 2.
In the title compound the pyridine ring shows boat
conformation. The dihedral angle between the least squares
plane of pyridine and phenyl ring is 85.92(13) A˚. For
N1–C2–C3–C7–C9–O10–O11–C12 and C4–C16–C17–
C18–C19–C20–C21, the dihedral angle is 86.13(11) A˚.
The atoms C4 and N1 deviates from Cremer and Pople
plane by 0.204(3) angstrom and 0.134(2) A˚, defined by the
atoms N1–C2–C3–C4–C5–C6. Pukering parameters also
confirms the structure, Q = 0.306 A˚, h = 106.4(4) and /
= 4.3(5). The torsion angle about C3–C9–O11–C12
being -177.8(2) and that about C4–C5–C13–C15 being
173.7(3) shows anti-periplanar and anti-periplanar con-
formation. The atoms C3–C4–C16–C17 gives syn-clinal
conformation with a value of 36.5(3). The structure
exhibits inter-molecular hydrogen bonds of the type
N–HO. N1–H1O14 has a length of 2.903(3) A˚ with an
angle of 177 along with the symmetry codes x, -1 ? y, z,
respectively. It has also intra-molecular hydrogen bonds of
the type C7–H7CO10 which has a length of 2.862(3) A˚
and an angle of 103. The stability of the crystal structure
can be accounted for by these hydrogen bonds.
Table 4 Atomic coordinates and equivalent thermal parameters of
the non-hydrogen atoms
Atom x y z Ueq
N1 0.2716(2) 0.8068(3) 0.4695(9) 0.0521(6)
C2 0.3415(3) 0.8376(3) 0.4259(1) 0.0487(6)
C3 0.3391(2) 1.0083(3) 0.40167(1) 0.0459(6)
C4 0.2470(3) 1.1532(3) 0.4172(1) 0.0460(6)
C5 0.2275(2) 1.1171(3) 0.4821(1) 0.0447(6)
C6 0.2290(2) 0.9409(3) 0.5027(1) 0.0462(6)
C7 0.4132(3) 0.6716(3) 0.4118(1) 0.0634(7)
C8 0.1907(3) 0.8690(4) 0.5585(1) 0.0617(7)
C9 0.4131(2) 1.0517(3) 0.3562(1) 0.0513(6)
O10 0.4779(2) 0.9474(3) 0.3338(1) 0.0777(7)
O11 0.4010(2) 1.2296(3) 0.3402(1) 0.0764(7)
C12 0.4651(4) 1.2870(5) 0.2940(2) 0.0947(1)
C13 0.2072(3) 1.2776(3) 0.5168(1) 0.0504(6)
O14 0.2212(2) 1.4304(2) 0.4968(9) 0.0719(6)
C15 0.1726(4) 1.2660(5) 0.5764(2) 0.0826(1)
C16 0.1004(3) 1.1705(3) 0.3647(1) 0.0526(7)
C17 0.0290(3) 1.0182(4) 0.3321(1) 0.0670(8)
C18 -0.1060(3) 1.0358(6) 0.2861(1) 0.0891(1)
C19 -0.1708(4) 1.2036(7) 0.2726(2) 0.0926(1)
C20 -0.1014(4) 1.3543(6) 0.3044(2) 0.0934(1)
C21 0.0344(3) 1.3393(4) 0.3503(1) 0.0740(9)
Ueq = (1/3)
P
i
P
j Uij(ai*aj*)(aiaj)
Table 5 Hydrogen-bonding geometry (A˚)
D–HA D–H H–A D–A D–HA Symmetry
codes
N(1)–H(1)O(14) 0.86 2.04 2.903(3) 177 x, -1 ? y, z
C(4)–H(4)O(11) 0.98 2.34 2.694(3) 100
C(4)–H(4)O(14) 0.98 2.37 2.752(3) 102
C(7)–H(7C)O(10) 0.96 2.15 2.862(3) 130
Note: D–H and H–A distances are essentially standard values and are
not derived from the experiment Fig. 2 ORTEP of the molecule with 50% probability
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